Go Deep
Rein Therapeutics Inc.
Rein Therapeutics Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,378 | -0.5 | 4.96 | 0.00 | 55.64 |
| Oct 2026 | 20,104 | -0.5 | 5.31 | 0.00 | 59.64 |
| Oct 2026 | 20,350 | -0.4 | 4.99 | 0.00 | 55.91 |
| Oct 2026 | 18,800 | -0.3 | 4.67 | 0.00 | 52.34 |
| Oct 2026 | 18,519 | -0.4 | 5.03 | 0.00 | 56.43 |
| Oct 2026 | 18,325 | -0.4 | 5.29 | 0.00 | 59.09 |
| Oct 2026 | 18,471 | -0.4 | 5.09 | 0.00 | 56.86 |
Rein Therapeutics Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -6,375,000.0 | -5,838,000.0 | -31,967,000.0 | -5,581,000.0 |
| EPS | -0.1 | -0.2 | — | -0.2 |
Rein Therapeutics Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -49,871,000.0 | -62,883,000.0 | -15,732,000.0 | -27,329,000.0 | — |
| EPS | -2.0 | -3.5 | -3.4 | -6.0 | — |
Rein Therapeutics Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 24,158,000.0 | 62,190,000.0 | 106,008,000.0 | 22,007,000.0 | — |
| Total Liabilities | 52,245,000.0 | 52,803,000.0 | 99,121,000.0 | 3,384,000.0 | — |
| Total Equity | -28,087,000.0 | 9,387,000.0 | 6,887,000.0 | 18,623,000.0 | — |
Owes vs Owns
Rein Therapeutics Inc. owed $0.85 for every $1 it owned in Jun 2026, up from $0.15 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.85× | 2.16× | 0.85× | 0.94× | 0.15× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Rein Therapeutics Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 13.3%Intangible assets 82.1%Other assets 4.6%
How it's funded — Dec 2025
Payables 7.6%Other liabilities 92.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 3.2 | 12.9 | 17.3 | 21.2 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 0.0 | 0.0 | 0.1 |
| Intangible assets | 19.8 | 48.5 | 85.5 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 1.1 | 0.8 | 3.1 | 0.7 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 4.0 | 0.9 | 1.2 | 1.7 |
| Other liabilities | 48.3 | 51.9 | 97.9 | 1.6 |
| Shareholders' equity | -28.1 | 9.4 | 6.9 | 18.6 |
| Net tangible assets | -47.9 | -39.1 | -78.6 | 18.6 |
Rein Therapeutics Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -19,361,000.0 | -22,291,000.0 | -19,808,000.0 | -24,865,000.0 | — |
| Investing Activities | — | 0.0 | 16,196,000.0 | 26,459,000.0 | -35,917,000.0 |
| Financing Activities | 9,755,000.0 | 17,818,000.0 | 15,794,000.0 | 0.0 | — |